EHA 2024: Topline findings of the TUD-APOLLO-064 trial and their potential clinical implications

During the European Hematology Association (EHA) 2024 Hybrid Congress, the AML Hub was pleased to speak with Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, What were the topline findings of the TUD-APOLLO-064 trial and their potential clinical implications?

Professor Platzbecker shares the study design and latest data from the TUD-APOLLO-064 trial of arsenic trioxide combined with all-trans retinoic acid (ATRA) and idarubicin vs standard ATRA and anthracycline-based chemotherapy for the treatment of newly diagnosed, high-risk acute promyelocytic leukemia (APL). Platzbecker discusses the promising event-free survival data favoring the novel combination, without an increase in toxicities or mortality compared with the comparator arm. Platzbecker closes by providing his insight on how these data may influence the future treatment paradigm for patients with high-risk APL.